Use of COVID-19 Drugs: A Brief Review on Indian Perspective

References

[1] Wu, Yi-Chi, Chen, Ching-Sung, Chan, Yu-Jiun (2020) The outbreak of COVID-19: An overview. J Chin Med Assoc. 83(3): 217-220 doi: 10.1097/JCMA.0000000000000270.

[2] Shi Z (2021) Du SRAS et du MERS à la COVID-19: un voyage pour comprendre les coronavirus des chauves-souris [From SARS, MERS to COVID-19: A journey to understand bat coronaviruses. Bull Acad Natl Med. 205(7): 732-736.

[3] Andrews MA, Areekal B, Rajesh KR, Krishnan J, Suryakala R, Krishnan B, Muraly CP, Santhosh PV (2020) First confirmed case of COVID-19 infection in India: A case report. Indian J Med Res. 151(5): 490-492. doi: 10.4103/ijmr.IJMR_2131_20.

[4] Pullen MF, Skipper CP, Hullsiek KH, Bangdiwala AS, Pastick KA, Okafor EC, Boulware DR, (2020) Symptoms of COVID-19 outpatients in the United States. In Open forum infectious diseases.  7(7): 271 US: Oxford University Press.

[5] Khan Z, Karataş Y, Ceylan AF, Rahman H (2021) COVID-19 and therapeutic drugs repurposing in hand: the need for collaborative efforts. Le Pharmacien Hospitalier et Clinicien, 56(1): 3-11.

[6] Stasi C, Fallani S, Voller F, Silvestri C (2020) Treatment for COVID-19: An overview. European journal of pharmacology. 889: 173644, doi: 10.1016/j.ejphar.2020.173644.

[7] World Health Organization, Tracking SARS-CoV-2 variants, https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/

[8] The Wikipedia, Variants of SARS-CoV-2, https://en.wikipedia.org/wiki/Variants_of_SARS-CoV-2.

[9] World Health Organization, 31 March 2021, https://www.who.int/news-room/feature-stories/detail/who-advises-that-ivermectin-only-be-used-to-treat-covid-19-within-clinical-trials

[10] Furuta Y, Komeno T, Nakamura T (2017) Favipiravir (T-705), a broad-spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 93(7): 449-463. doi: 10.2183/pjab.93.027.

[11] Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, Patil S, Barkate H. (2021) Role of favipiravir in the treatment of COVID-19. Int J Infect Dis. 102: 501-508. doi: 10.1016/j.ijid.2020.10.069.

[12] Wikipedia, Methylprednisolone, https://en.wikipedia.org/wiki/Methylprednisolone.

[13] World Health Organization, 16 October 2021, Coronavirus disease (COVID-19) Dexamethasone, https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-covid-19-dexamethasone.

[14] Gupta S, Leaf D E (2021) Tocilizumab in COVID-19: some clarity amid controversy. The Lancet, 397(10285): 1599-1601.

[15] Billett HH, Reyes-Gil M, Szymanski J, Ikemura K, Stahl LR, Lo Y, Rahman S, Gonzalez-Lugo JD, Kushnir M, Barouqa M, Golestaneh L, Bellin E. (2020) Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality. Thromb Haemost. 120(12):1691-1699. doi: 10.1055/s-0040-1720978.

[16] Drago F, Gozzo L, Li L, Stella A, Cosmi B (2020) Use of Enoxaparin to Counteract COVID-19 Infection and Reduce Thromboembolic Venous Complications: A Review of the Current Evidence. Frontiers in pharmacology, 11: 579886. https://doi.org/10.3389/fphar.2020.579886.

[17] Al-Khikani FHO (2020) Amphotericin B as antiviral drug: Possible efficacy against COVID-19. Ann Thorac Med. 15(3):118-124. doi: 10.4103/atm.ATM_147_20.

@article{1703737,
      author = {Pankaj Sarkar},
      title = {Use of COVID-19 Drugs: A Brief Review on Indian Perspective},
      journal = {Iconic Research And Engineering Journals},
      year = {2022},
      volume = {6},
      number = {2},
      pages = {24-31},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1703737.pdf},
      abstract = {The first evidence of severe acute respiratory syndrome corona virus-2 (SARS CoV-2) was traced in Wuhan city, China, in December2019. The global outbreak of the novel coronavirus surpassed in early 2020. Because of the mutation of coronavirus, a large number of mutated strains have been observed in various countries. WHO designated the most important and rapid spreading variants as alpha, beta, gamma, delta, and omicron. The rapid clinical trial of several drugs has been started since early 2019 for the treatment of patients infected by the novel coronavirus. At the beginning of the pandemic, some drugs such as chloroquine and hydroxychloroquine were recommended for treatment of the covid-19 patients without any adequate clinical trials. The drugs used for the treatment of coronavirus infection can be divided into protocol drugs and non-protocol drugs. Here, the efficacy of several protocol and non-protocoldrugs towards the prevention and treatment of coronavirus infection, their interaction with coronavirus, and side effects of such recommended drugs are described in this chapter.},
      month = {August},
  }